A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Immune Markers After Minimum Maintenance Dose
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Food allergy immunotherapies (Primary) ; Omalizumab (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 21 Sep 2017 Last checked against ClinicalTrials.gov record
- 17 Sep 2017 Planned End Date changed from 31 Mar 2019 to 31 Jul 2019.
- 17 Sep 2017 Planned primary completion date changed from 31 Dec 2018 to 1 Jul 2018.